UBS AG Upgrades Vertex Pharmaceuticals to Buy (VRTX)
A number of other analysts have also recently weighed in on VRTX. Analysts at Morgan Stanley (NYSE: MS) cut their price target on shares of Vertex Pharmaceuticals from $51.00 to $46.00 in a research note to investors on Tuesday. Separately, analysts at JPMorgan Chase (NYSE: JPM) reiterated an “overweight” rating on shares of Vertex Pharmaceuticals in a research note to investors on Tuesday. Finally, analysts at Wells Fargo & Co. (NYSE: WFC) reiterated an “outperform” rating on shares of Vertex Pharmaceuticals in a research note to investors on Tuesday.
Vertex Pharmaceuticals opened at 56.92 on Tuesday. Vertex Pharmaceuticals has a 1-year low of $26.50 and a 1-year high of $58.87. The company has a market cap of $12.014 billion and a price-to-earnings ratio of 41.08.
Vertex Pharmaceuticals last released its earnings data on Thursday, April 26th. The company reported $0.43 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.57 by $0.14. The company’s revenue for the quarter was up 496.5% on a year-over-year basis. Analysts expect that Vertex Pharmaceuticals will post $0.71 EPS next quarter.
Vertex Pharmaceuticals Incorporated (Vertex) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases.